Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Chemotherapy Cycles and Ovarian Clear Cell Carcinoma

Gynecol Oncol; ePub 2016 Dec 12; Prendergast, et al

Survival rates for women with stage I-II ovarian clear cell carcinoma (OCCC) were similar after 3 or 6 cycles of platinum-based chemotherapy, a recent study found, and patients with early stage I and II OCCC may be candidates for a 3-cycle treatment approach. The cohort included 210 patients (median age 53 years) with stage I-II OCCC treated at 5 institutions from January 1994 through December 2011 and identified and divided into 2 groups: those who received 3 vs 6 cycles of adjuvant chemotherapy. Researchers found:

  • All patients received adjuvant chemotherapy with 90% receiving carboplatin and paclitaxel.
  • 38 (18.1%) patients received 3 cycles, and 172 (81.9%) patients received 6 cycles of adjuvant treatment.
  • Recurrence rate was comparable between groups (18.4% vs 27.3% for 3 vs 6 cycles).
  • No impact of 3 vs 6 cycles of chemotherapy on progression-free survival was observed.
  • No benefit was found in more chemotherapy in stratified analysis by stage nor on multivariate analysis adjusting for the impact of stage.


Prendergast EN, Holzapfel M, Mueller JJ, et al. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma – A multi-institutional cohort. [Published online ahead of print December 12, 2016]. Gynecol Oncol. doi:10.1016/j.ygyno.2016.12.004.